Answers are grounded in this paper and cite their sources.
Demonstrates enhanced antitumor immunity in tumor models using a bispecific drug conjugate, indicating effective macrophage and T-cell targeting.
Programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) are identified as key immune checkpoints on tumor-infiltrating macrophages, beyond their roles in T-cell functions. Blockade of LAG-3 and PD-1 pathways skews M2 macrophage polarization and shows antitumor efficacy independent of T cells. A bispecific peptide–drug conjugate, BsPep-IMDQ, was developed to simultaneously block both pathways and deliver a Toll-like receptor 7/8 (TLR7/8) agonist, imidazoquinoline (IMDQ), via a matrix metalloproteinase (MMP)-cleavable linker. This conjugate demonstrated potent tumor suppression in both anti-PD-1-responsive MC38 and -resistant B16 tumor models, promoting M1 macrophage polarization and CD8+ T-cell activation, while minimizing systemic toxicity. This work highlights macrophage targeting as a promising strategy for cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: